Lastifluno (Azelastine Hydrochloride, Fluticasone Propionate)

Azelastine hydrochloride is an H1‑histamine receptor antagonist. By blocking these receptors on nasal mucosal cells, it prevents histamine‑mediated responses such as itching, sneezing, and vasodilation, thereby reducing the immediate allergic symptoms experienced during rhinitis.

The dosing regimen for Lastifluno is determined by the prescribing clinician based on the patient’s age, severity of symptoms, and response to therapy. Typically, the spray is administered once or twice daily, but exact dosing instructions should be obtained from a qualified healthcare professional.

Safety data for Lastifluno in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lastifluno. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with monotherapy antihistamine sprays, Lastifluno adds a corticosteroid component, offering both rapid symptom relief and longer‑term reduction of nasal inflammation. This dual mechanism can provide superior control of congestion and mucosal edema for patients whose symptoms are not fully managed by a single‑agent therapy.

Store Lastifluno at room temperature, preferably below 25 °C, in its original packaging. Protect the bottle from moisture, excessive heat, and direct sunlight. Keep the spray cap tightly closed when not in use to maintain product stability.

Lastifluno is administered as an intranasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator while breathing in gently. The same procedure is repeated in the other nostril if a bilateral dose is prescribed.

Serious adverse events, although rare, include nosebleeds (epistaxis), perforation of the nasal septum, severe allergic reactions such as anaphylaxis, and visual disturbances. Patients should seek immediate medical attention if they experience uncontrolled bleeding, sudden vision changes, or signs of a systemic allergic reaction.

Lastifluno should be avoided in individuals with known hypersensitivity to azelastine, fluticasone, or any of the formulation excipients. It is also contraindicated in patients who have experienced severe nasal septum perforation or uncontrolled nasal infections until the condition resolves.